Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Exact Sciences Corp (NASDAQ: EXAS) closed at $101.13 in the last session, down -0.12% from day before closing price of $101.25. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 8.96 million shares were traded. EXAS stock price reached its highest trading level at $101.365 during the session, while it also had its lowest trading level at $100.985.
Ratios:
We take a closer look at EXAS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 77.67. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 1.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 19 ’25 when ORVILLE JACOB A sold 5,000 shares for $75.00 per share. The transaction valued at 375,000 led to the insider holds 23,237 shares of the business.
Herriott James sold 1,000 shares of EXAS for $70,000 on Nov 19 ’25. The SVP, General Counsel & Sec now owns 11,585 shares after completing the transaction at $70.00 per share. On Nov 19 ’25, another insider, ORVILLE JACOB A, who serves as the Officer of the company, bought 5,000 shares for $75.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 19191017472 and an Enterprise Value of 20693211136. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.23 while its Price-to-Book (P/B) ratio in mrq is 7.66. Its current Enterprise Value per Revenue stands at 6.714 whereas that against EBITDA is 191.641.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.41, which has changed by 0.6210375 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $101.87, while it has fallen to a 52-week low of $38.81. The 50-Day Moving Average of the stock is 43.35%, while the 200-Day Moving Average is calculated to be 84.52%.
Shares Statistics:
According to the various share statistics, EXAS traded on average about 4.90M shares per day over the past 3-months and 17059430 shares per day over the past 10 days. A total of 189.45M shares are outstanding, with a floating share count of 186.70M. Insiders hold about 1.62% of the company’s shares, while institutions hold 94.47% stake in the company. Shares short for EXAS as of 1763078400 were 7359833 with a Short Ratio of 1.50, compared to 1760486400 on 7968887. Therefore, it implies a Short% of Shares Outstanding of 7359833 and a Short% of Float of 4.44.
Earnings Estimates
The company has 8.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.1, with high estimates of $0.24 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.56 and $0.04 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is $1.12, with 8.0 analysts recommending between $1.52 and $0.63.
Revenue Estimates
According to 20 analysts,. The current quarter’s revenue is expected to be $860.75M. It ranges from a high estimate of $864.8M to a low estimate of $855.9M. As of. The current estimate, Exact Sciences Corp’s year-ago sales were $713.42MFor the next quarter, 20 analysts are estimating revenue of $831.95M. There is a high estimate of $854.03M for the next quarter, whereas the lowest estimate is $774.68M.
A total of 21 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $3.23B, while the lowest revenue estimate was $3.22B, resulting in an average revenue estimate of $3.23B. In the same quarter a year ago, actual revenue was $2.76BBased on 21 analysts’ estimates, the company’s revenue will be $3.67B in the next fiscal year. The high estimate is $3.76B and the low estimate is $3.48B.
